Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, TRI

HepaTx Enters Collaboration with Mayo Clinic to Advance Cell Therapy Technology for Liver Disease to Clinical Trials


PALO ALTO, Calif., Sept. 10, 2024 /PRNewswire/ -- HepaTx, a biotechnology company specializing in regenerative medicine, has entered into a license agreement with Mayo Clinic to advance HepaTx's innovative stem cell technology into clinical trials. This collaboration aims to develop and evaluate new therapeutic approaches for liver diseases, with an initial focus on alcohol-related hepatitis, offering hope to millions of patients worldwide.

Under the agreement, HepaTx will leverage Mayo Clinic's clinical research expertise and infrastructure to facilitate the transition of its proprietary technology, which uses adipose-derived stem cells for the potential treatment of acute and chronic liver conditions, from preclinical development to human trials.

"We are very pleased to have the opportunity to work with the outstanding researchers at Mayo Clinic to advance these potentially transformative therapies to the clinic. I can think of no better organization to work with given their outstanding liver disease and regenerative medicine expertise," commented Eric Schuur, the CEO of HepaTx.

The collaboration is expected to accelerate the development of HepaTx's cell therapy technology, enabling it to reach the clinical stage more quickly and efficiently. The overall aim of the effort is to advance the pipeline of innovative cell therapies that can potentially transform the treatment landscape for liver disease patients, improving outcomes and quality of life.

About HepaTx

HepaTx is a cell therapy and regenerative medicine company developing cell-based treatments for late-stage liver disease, a highly underserved and cost-intensive market. To learn more, visit our website, Hepatx.com, and follow us on Twitter, @hepatx, and LinkedIn.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

SOURCE HepaTx


These press releases may also interest you

at 13:41
Mississauga's small and medium-sized businesses keep main streets flourishing across the city, create well-paying jobs and deliver the dream of entrepreneurship. It is essential that these businesses thrive so they can continue being the bedrock of...

at 13:35
Centering Healthcare Institute (CHI) is pleased to announce the receipt of a $7.6 million investment from The Studio @ Blue Meridian. This funding will support a three-year strategic plan designed to bolster CHI in becoming a strong, evolved...

at 13:30
Canada Economic Development for Quebec Regions (CED) Montréal's East End has the assets and potential to become a leading hub for economic and social development in Quebec. Recognizing this potential, the Government of Canada has committed to...

at 13:26
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:...

at 13:14
WellQuest Living, a prominent senior housing owner, operator, and developer, is thrilled to announce the appointment of Connor MacLennan as its new Chief Investment Officer (CIO). MacLennan, who joins WellQuest Living from PGIM, brings a wealth of...

at 13:11
26North Partners LP ("26North"), a next-generation alternatives firm founded by Josh Harris, announced today that it has acquired leading health club operator Onelife Fitness from Delos Capital ("Delos"). With locations across the Mid-Atlantic and...



News published on and distributed by: